Digestive Health & Gastroenterology Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide

This Phase 4 study by Montefiore Medical Center is comparing two anti-nausea drugs, fosaprepitant and metoclopramide, in adults experiencing nausea and vomiting. Patients visiting emergency care for these symptoms may benefit from a new treatment option if fosaprepitant proves to be more effective or causes fewer side effects than the current standard. This trial is important because it could improve comfort and recovery for people dealing with distressing nausea and vomiting.

Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of Obesity

Researchers at Nantes University Hospital are testing a 12-week daytime restricted eating plan in adults with obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). This study explores whether limiting food intake to certain daytime hours can reduce liver fat without medication. If successful, this approach could offer a simple lifestyle change to improve liver health for those affected by fatty liver disease.

Probiotic For the Improvement of Environmental Enteropathy in Pregnant Women in Senegal

This Phase 2 trial conducted by Institut Pasteur de Dakar is investigating whether a probiotic can improve gut health in pregnant women with environmental enteropathy, a condition linked to poor nutrient absorption and child stunting. Improving gut function during pregnancy might help reduce the risk of stunted growth in children. Results are not yet available, but this research could lead to new ways to support maternal and child health in affected communities.

Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

The University of Colorado, Denver is comparing two biopsy methods to find which better detects precancerous changes in patients with Barrett's esophagus. Early identification of abnormal cells can prevent progression to esophageal cancer and improve monitoring strategies. This study includes adults diagnosed or suspected with Barrett's esophagus and aims to enhance screening effectiveness.

Dihydroartemisinin for MAFLD

A Phase 1 trial at The First Affiliated Hospital with Nanjing Medical University is testing an oral medication called Dihydroartemisinin for adults with Metabolic Associated Fatty Liver Disease (MAFLD). This early-stage study explores whether this pill can safely reduce liver fat and improve liver health. If promising, it may lead to new treatment options for people with fatty liver disease.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.